FIELD: medicine.
SUBSTANCE: treating cerebral oedema is ensured by administering Raleukin, a preparation of receptor recombinant interleukin-1 antagonist intravenously in a dose of 25-100 mg/kg of body weight.
EFFECT: reducing an intensity of oedema both unassisted, and assisted by other medicinal products.
2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATMENT OF CEREBROVASCULAR BRAIN DISORDERS (OPTIONS) | 2017 |
|
RU2659674C1 |
| COMPOSITION FOR NEUROPROTECTION AND STIMULATION OF BRAIN NEUROREGENERATION AFTER INJURY, AGENT BASED ON IT, A METHOD OF ITS PRODUCTION AND USE | 2022 |
|
RU2803286C1 |
| METHOD FOR STROKE TREATMENT | 2014 |
|
RU2571282C1 |
| METHOD OF DETERMINING INDICATIONS FOR CARRYING OUT INTRAVENOUS THROMBOLYTIC THERAPY IN ACUTE PERIOD OF ISCHEMIC STROKE | 2010 |
|
RU2444990C1 |
| METHOD OF IMMUNOTHERAPY OF PURULENT RHINOSINUSITIS | 2010 |
|
RU2457789C2 |
| METHOD FOR PREPARING A PREPARATION BASED ON MAGNETIC NANOPARTICLES (MNCH) OF IRON OXIDE FOR MRT-DIAGNOSIS OF NEOPLASMS | 2017 |
|
RU2659949C1 |
| METHOD FOR TREATING METASTATIC CEREBRAL LESIONS | 2000 |
|
RU2238731C2 |
| THERAPY OF CRANIOCEREBERAL INJURY | 2008 |
|
RU2366466C1 |
| MEANS FOR TREATING ISCHEMIA OF VASCULAR BRAINS | 2016 |
|
RU2625740C1 |
| PHARMACOLOGICAL NEUROPROTECTIVE DRUG | 2014 |
|
RU2561045C1 |
